NVO

Bagsværd, 5 February 2025 - Financial report for the period 1 January 2024 to 31 December 2024

Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong...

U.S.-listed shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are up 3.5% premarket, following a bull note from UBS.

Bagsværd, Denmark and Lexington, Massachusetts, US, 8 January 2025 – Novo Nordisk A/S and Valo Health, Inc. today announced they...

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the...

Variant Bio today announced a partnership with Novo Nordisk for disease research and development that could total $50 million for...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a...

Novo Nordisk A/S NVO, the Danish pharmaceutical giant behind weight-loss drugs Wegovy and Saxenda, is facing scrutiny over its sponsorship...

Novo Nordisk (NVO 0.15%) has sparked investor interest primarily because of its weight loss treatments.

Novo Nordisk (NVO 0.15%) has found phenomenal success in treating patients with obesity and diabetes.